<?xml version="1.0" encoding="UTF-8"?>
<ref id="bb0180">
 <label>36</label>
 <element-citation publication-type="journal" id="rf0175">
  <person-group person-group-type="author">
   <name>
    <surname>Smolen</surname>
    <given-names>J.S.</given-names>
   </name>
   <name>
    <surname>Landew√©</surname>
    <given-names>R.B.M.</given-names>
   </name>
   <name>
    <surname>Bijlsma</surname>
    <given-names>J.W.J.</given-names>
   </name>
   <name>
    <surname>Burmester</surname>
    <given-names>G.R.</given-names>
   </name>
   <name>
    <surname>Dougados</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Kerschbaumer</surname>
    <given-names>A.</given-names>
   </name>
  </person-group>
  <article-title>EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update</article-title>
  <source>Ann Rheum Dis</source>
  <year>2020</year>
  <pub-id pub-id-type="doi">10.1136/annrheumdis-2019-216655</pub-id>
 </element-citation>
</ref>
